EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:

2026 Wells Fargo Healthcare Conference

Format: Fireside chat and investor meetings

Date: Wednesday, September 9^th, 2026

Time: 4:30 p.m. ET

Morgan Stanley 24^th Annual Global Healthcare Conference

Format: Fireside chat and investor meetings

Date: Monday, September 14^th, 2026

Time: 4:05 p.m. ET

H.C. Wainwright 28^th Annual Global Investment Conference

Format: Fireside chat and investor meetings

Date: Tuesday, September 15^th, 2026

Time: 11:30 a.m. ET

Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. Archived replays of all events will be available on the website for approximately 90 days following the conference.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases. Kyverna’s lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis. The Company is also harnessing other KYSA trials and investigator-initiated trials, as well as next generation innovations to expand patient access and evaluate future indications. For more information, please visit https://kyvernatx.com.

Contact:

Investors: InvestorRelations@kyvernatx.com

Media: media@kyvernatx.com